Randomized clinical studies of anti-tumor vaccination: State of the art in 2008

Expert Review of Vaccines

Volumn 8, Issue 1, 2009, Pages 51-66

  Fournier, Philippe ^a   Schirrmacher, Volker ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Allogenic; Antigen specific; Autologous; Cancer vaccine; Immunotherapy; Progression free survival; Survival; Therapeutic; Whole cell

Indexed keywords

ALLOVECTIN 7; AVICINE; BIOVAXID; CANVAXIN; CARCINOEMBRYONIC ANTIBODY; CEAVAC; CHORIONIC GONADOTROPIN BETA SUBUNIT; DNA VACCINE; EPIDERMAL GROWTH FACTOR; GANGLIOSIDE GM2; GASTRIN 17; INSEGIA; LUCANIX; MELACINE; MELANOMA ANTIGEN 3; MELANOMA VACCINE; MITUMOMAB; MONOCLONAL ANTIBODY; MUCIN 1; ONYVAX 105; PANVAC VF; PLASMID DNA; PLASMID VECTOR; POLYCLONAL ANTIBODY; PROSTVAC VF; PROVENGE; RENALE; SCV 106; STIMUVAX; THERATOPE; TUMOR ANTIGEN; TUMOR CELL VACCINE; TUMOR VACCINE; UNCLASSIFIED DRUG; VACCINIA ONCOLYSATE; VIRUS VECTOR; VITESPEN;

ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG RESEARCH; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TUMOR IMMUNOLOGY;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 58149396487     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.8.1.51     Document Type: Review

References (121)

1. Matzinger P. An innate sense of danger. Ann. NY Acad. Sci. 961, 341-342 (2002).
2. Shapiro J, Marshall J, Karasek P et al. G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: results of a randomized, double-blind, multinational, multicenter study. J. Clin. Oncol. 23(Suppl. 16), Abstract 4012 (2005).
3. Gilliam AD, Topuzov EG, Garin AM et al. Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy. J. Clin. Oncol. 22(14), (Suppl. 14), Abstract 2511 (2004).
4. He AR, Marshall JL. Clinical experiences with G17DT in gastrointestinal malignancies. Expert Rev. Anticancer Ther. 6(4), 487-492 (2006).
5. Holmberg LA, Sandmaier BM. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev. Vaccines 3(6), 655-663 (2004).
6. Miles DW, Towlson KE, Graham R et al. A randomised Phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br. J. Cancer. 74(8), 1292-1296 (1996).
7. Miles D, Cameron D, Dodwell D et al. Pretreatment chemotherapy (CX) regimen and responses in 1028 metastatic breast cancer (MBC) patients from an international, randomized Phase III clinical trial of STn-KLH therapeutic vaccine. Proc. Am. Soc. Clin. Oncol. 22, 55 (2003).
8. Mayordomo J, Tres A, Miles D, Finke L, Jenkins H. Long term follow-up of patients concomittantly treated with hormone therapy in a prospective randomized multicenter clinical study comparing STn-KLH with KLH as control in stage IV breast cancer following first-line chemotherapy. ASCO Proc. 22, 2603 (2004).
9. Ibrahim NK, Murray J, Parker J, Finkes L, Miles D. Humoral immune response to naturally occuring STn in metastatic breast cancer patients (MBC pts) treated with STn-KLH vaccine. ASCO Proc. 22, 2547 (2004).
10. Curigliano G, Rescigno M, Goldhirsch A. Immunology and breast cancer: therapeutic cancer vaccines. Breast. 16(Suppl. 2), S20-S26 (2007).
11. Butts C, Murray N, Maksymiuk A et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 23(27), 6674-6681 (2005).
12. Apostolopoulos V, Pietersz GA, Tsibanis A et al. Pilot Phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 8(3), R27 (2006).
13. Knutson KL. GMK (Progenics Pharmaceuticals). Curr. Opin. Investig. Drugs 3(1), 159-164 (2002).
14. Helling F, Calves M, Shang Y, Oettgen HF, Livingston PO. Construction of immunogenic GD3-conjugate vaccines. Ann. NY Acad. Sci. 690, 396-397 (1993).
15. Livingston PO. Approaches to augmenting the IgG antibody response to melanoma ganglioside vaccines. Ann. NY Acad. Sci. 690, 204-213 (1993).
16. Livingston PO. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin. Cancer Res. 10(14), 4717-4723 (2004).
17. Livingston PO, Wong GY, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12(5), 1036-1044 (1994).
18. 2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19(9), 2370-2380 (2001).
19. Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19(9), 2370-2380 (2001).
20. Vansteenkiste J, Zielinski M, Dahabre J et al. Multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3-positive, completely resected, non-small cell lung cancer (NSCLC). J. Clin. Oncol. 24(1), (Suppl. 18S), Abstract 7019 (2006).
21. Gonzalez G, Crombet T, Torres F et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann. Oncol. 14(3), 461-466 (2003).
22. Neninger Vinageras E, de la Torre A, Osorio Rodríguez M et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J. Clin. Oncol. 26(9), 1452-1458 (2008).
23. García B, Neninger E, de la Torre A et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin. Cancer Res. 14(3), 840-846 (2008).
24. Triozzi PL, Gochnour D, Martin EW et al. Clinical and immunological effects of a synthetic β-human chorionic gonadotropin vaccine. Int. J. Oncol., 5, 1447-1454 (1994).
25. Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a β-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer, antibody response is associated with improved survival. Clin. Cancer Res. 8(7), 2044-2051 (2002).
26. Melanoma Study Group of the Mayo Clinic Cancer Center, Celis E. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer 110(1), 203-214 (2007).
27. Markovic SN, Suman VJ, Ingle JN et al. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am. J. Clin. Oncol. 29(4), 352-360 (2006).
28. Hamid O, Solomon JC, Scotland R et al. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin. Cancer Res. 13(1), 215-222 (2007).
29. Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J. Clin. Oncol. 22(22), 4474-4485 (2004).
30. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA et al. Immunologic and clinical outcomes of a randomized Phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin. Cancer Res. 13(21), 6386-6395 (2007).
31. Gonzalez R, Hutchins L, Nemunaitis J, Atkins M, Schwarzenberger PO. Phase 2 trial of allovectin-7 in advanced metastatic melanoma. Melanoma Res. 16(6), 521-526 (2006).
32. Petrulio CA, Kaufman HL. Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev. Vaccines 5(1), 9-19 (2006).
33. Kaufman HL, Wang W, Manola J et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 22(11), 2122-2132 (2004).
34. Kaufman HL, Wang W, Manola J et al. Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: follow-up clinical results from ECOG 7897. 2005 ASCO Annual Meeting. J. Clin. Oncol. 23,(Suppl. 16) Abstract 4501 (2005).
35. de Cerio AL, Zabalegui N, Rodríguez-Calvillo M, Inogés S, Bendandi M. Anti-idiotype antibodies in cancer treatment. Oncogene 26(25), 3594-3602 (2007).
36. McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin. Cancer Res. 2(4), 679-686 (1996).
37. Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus bacillus Calmette-Guérin. Clin. Cancer Res. 5(6), 1319-1323 (1999).
38. Yao TJ, Meyers M, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin. Cancer Res. 5(1), 77-81 (1999).
39. Giaccone G, Debruyne C, Felip E et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J. Clin. Oncol. 23(28), 6854-6864 (2005).
40. Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J. Clin. Oncol. 17(9), 2889-2885 (1999).
41. Krug LM, Grant SC, Miller VA, Ng KK, Kris MG. Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination. Semin. Oncol. 26(5 Suppl. 15), 55-61 (1999).
42. Posner MC, Niedzwiecki D, Venook AP et al. A Phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann. Surg. Oncol. 15(1), 158-164 (2008).
43. Blumenthal RD. Technology evaluation: Onyvax-105, Onyvax. Curr. Opin. Mol. Ther. 5(6), 668-672 (2003).
44. Maxwell-Armstrong CA, Durrant LG, Buckley TJ et al. Randomized double-blind Phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br. J. Cancer 84(11), 1443-1446 (2001).
45. Maxwell-Armstrong C. Studies using the anti-idiotypic monoclonal antibody 105AD7 in patients with primary and advanced colorectal cancer. Ann. R. Coll. Surg. Engl. 84(5), 314-318 (2002).
46. Ullenhag GJ, Spendlove I, Watson NF et al. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin. Cancer Res. 12(24), 7389-7396 (2006).
47. Samonigg H, Wilders-Truschnig M, Kuss I et al. A double-blind randomized-Phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer. J. Immunother. 22(6), 481-488 (1999).
48. Redfern CH, Guthrie TH, Bessudo A et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J. Clin. Oncol. 24(19), 3107-3112 (2006).
49. Flowers CR. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma. Expert Rev. Vaccines 6(3), 307-317 (2007).
50. Lee ST, Jiang YF, Park KU, Woo AF, Neelapu SS. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. Expert Opin. Biol. Ther. 7(1), 113-122 (2007).
51. Neelapu SS, Gause BL, Nikcevich DA et al. Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report. Clin. Lymphoma 6(1), 61-64 (2005). • Promising results against lymphomas that are near completion in a Phase III randomized trial.
52. Morton DL, Foshag LJ, Hoon DS et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216(4), 463-482 (1992); erratum: Ann. Surg. 217(3), 309 (1993).
53. Morton DL, Hsueh EC, Essner R et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann. Surg. 236(4), 438-448 (2002).
54. Hsueh EC, Gupta RK, Qi K, Morton DL. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J. Clin. Oncol. 16(9), 2913-2920 (1998).
55. Morton DL. Presented at: 58th Annual Meeting of the Society of Surgical Oncology. Atlanta, GA, USA, 3-6 March 2006.
56. Hsueh EC, Famatiga E, Gupta RK, Qi K, Morton DL. Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): correlation with survival. Ann. Surg. Oncol. 5(7), 595-602 (1998).
57. Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of belagenpumatucel-L, a transforming growth factor β-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24(29), 4721-4730 (2006).
58. Mitchell MS, Von Eschen KB. Phase III trial of Melacine melanoma vaccine versus combination chemotherapy in the treatment of stage IV melanoma. Proc. Am. Soc. Clin. Oncol. 16, 496 (1997).
59. Mitchell MS. Immunotherapy as part of combinations for the treatment of cancer. Int. Immunopharmacol. 3(8), 1051-1059 (2003).
60. Sondak VK, Liu PY, Tuthill RJ et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J. Clin. Oncol. 20(8), 2058-2066 (2002).
61. Sosman JA, Unger JM, Liu PY et al. Southwest Oncology Group. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J. Clin. Oncol. 20(8), 2067-2075 (2002).
62. Mitchell MS, Abrams J, Thompson JA et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon ?-2b compared with high-dose interferon ?-2b for resected stage III cutaneous melanoma. J. Clin. Oncol. 25(15), 2078-2085 (2007).
63. Sosman JA, Sondak VK. Melacine: an allogeneic melanoma tumor cell lysate vaccine. Expert Rev. Vaccines 2(3), 353-368 (2003).
64. Mitchell MS, Harel W, Groshen S. Association of HLA phenotype with response to active specific immunotherapy of melanoma. J. Clin. Oncol. 10(7), 1158-1164 (1992).
65. Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A. Lessons from randomized Phase III studies with active cancer immunotherapies - outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 25(Suppl. 2), B97-B109 (2007).
66. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin. Cancer Res. 7(7), 1882-1887 (2001). • Reports a double-blind, prospectively randomized, placebo-controlled trial with a polyvalent, shed antigen melanoma vaccine that shows a 2.5-times longer median time to disease progression in patients treated with melanoma vaccine compared with that in patients treated with placebo vaccine. However, overall survival in the vaccinated patients was not significantly increased when compared with the group of patients treated with placebo.
67. Reynolds S, Kiken D, Zeleniuch-Jacquotte A et al. Clinical trial with melanoma vaccine. Am. Soc. Clin. Oncol. 22, 724 (2003) (Abstract 2913).
68. Reynolds SR, Albrecht J, Shapiro RL et al. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin. Cancer Res. 9(4), 1497-1502 (2003).
69. + T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin. Cancer Res. 9(2), 657-662 (2003).
70. Wallack MK, Sivanandham M, Balch CM et al. A Phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 75(1), 34-42 (1995).
71. Wallack MK, Sivanandham M, Whooley B, Ditaranto K, Bartolucci AA. Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial. Ann. Surg. Oncol. 3(2), 110-117 (1996).
72. Wallack MK, Sivanandham M, Ditaranto K et al. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a Phase III, multi-institutional trial. Ann. Surg. 226(2), 198-206 (1997).
73. Wallack MK, Sivanandham M, Balch CM et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a Phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J. Am. Coll. Surg. 187(1), 69-77 (1998).
74. Kim EM, Sivanandham M, Stavropoulos CI, Bartolucci AA, Wallack MK. Overview analysis of adjuvant therapies for melanoma - a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials. Surg. Oncol. 10(1-2), 53-59 (2001).
75. Hersey P, Coates AS, McCarthy WH et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J. Clin. Oncol. 20(20), 4181-4190 (2002).
76. Hoover HC Jr, Brandhorst JS, Peters LC et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a Phase III prospectively randomized trial. J. Clin. Oncol. 11(3), 390-399 (1993).
77. Harris JE, Ryan L, Hoover HC Jr et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol. 18(1), 148-157 (2000).
78. Vermorken JB, Claessen AM, van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353(9150), 345-350 (1999).
79. Uyl-de Groot CA, Vermorken JB, Hanna MG et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 23(17-18), 2379-2387 (2005).
80. Hanna MG Jr, Hoover HC Jr, Vermorken JB, Harris JE, Pinedo HM. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized Phase III trials show promise. Vaccine 19(17-19), 2576-2582 (2001).
81. Galligioni E, Francini M, Quaia M et al. Randomized study of adjuvant immunotherapy with autologous tumor cells and BCG in renal cancer. Ann. NY Acad. Sci. 690, 367-369 (1993).
82. Galligioni E, Quaia M, Merlo A et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 77(12), 2560-2566 (1996).
83. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 363(9409), 594-599 (2004). • Data is from a randomized Phase III trial of individually prepared autologous tumorderived product, given in the adjuvant setting after nephrectomy for renal cancer. Shows a better progression-free survival but not a better overall survival within the group of treated patients.
84. Amato RJ. Heat-shock protein-peptide complex-96 for the treatment of cancer. Expert Opin. Biol. Ther. 7(8), 1267-1273 (2007).
85. Wood CG, Escudier B, Gorelov S et al. A multicenter randomized study of adjuvant heat-shock protein peptidecomplex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC) - a preliminary report. J. Clin. Oncol. 22(Suppl. 14), Abstract 2618 (2004).
86. Wood C, Srivastava P, Bukowski R et al. C-100-112 RCC Study Group. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised Phase III trial. Lancet 372(9633), 145-154 (2008).
87. Richards J, Testori A, Whitman E et al. Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized Phase III trial in stage IV melanoma. J. Clin. Oncol. 24(Suppl. 18), Abstract 8002 (2006).
88. Testori A, Richards J, Whitman E et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-121 Study Group. J. Clin. Oncol. 26(6), 955-962 (2008).
89. Kuang M, Peng BG, Lu MD et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin. Cancer Res. 10(5), 1574-1579 (2004). •• Reports that vaccination with autologous formalin-fixed tumor vaccine is beneficial for patients with hepatocellular carcinoma in terms of progression-free survival and overall survival.
90. Peng BG, Liang LJ, He Q et al. Tumor vaccine against recurrence of hepatocellular carcinoma. World J. Gastroenterol. 11(5), 700-704 (2005).
91. Ohno T. Autologous formalin-fixed tumor vaccine. Curr. Pharm. Des. 11(9), 1181-1188 (2005).
92. Peng BG, Liang LJ, He Q et al. Use of autologous tumor vaccine in preventing recurrence of hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 13(10), 772-775 (2005).
93. Peng B, Liang L, Chen Z et al. Autologous tumor vaccine lowering postsurgical recurrent rate of hepatocellular carcinoma. Hepatogastroenterology 53(69), 409-414 (2006).
94. Ockert D, Schirrmacher V, Beck N et al. Newcastle disease virus infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin. Cancer Res. 2, 21-28 (1996).
95. Schlag P, Manasterski M, Gerneth Th et al. Active specific immunotherapy with NDV modified autologous tumor cells following liver metastases resection in colorectal cancer: First evaluation of clinical response of a Phase II trial. Cancer Immunol. Immunother. 35, 325-330 (1992).
96. Schirrmacher V, Ahlert T, Pröbstle T et al. Immunization with virus-modified tumor cells. Semin. Oncol. 25(6), 677-696 (1998).
97. Steiner HH, Bonsanto MM, Beckhove P et al. Anti-tumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety and clinical benefit. J. Clin. Oncol. 22(21), 4272-4281 (2004).
98. Ahlert T, Sauerbrei W, Bastert G et al. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J. Clin. Oncol. 15(4), 1354-1366 (1997).
99. Karcher J, Dyckhoff G, Beckhove P et al. Anti-tumor vaccination with HNSCC with autologous virus-modified tumor cells. Cancer Res. 64(21), 8057-8061 (2004).
100. Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol. Immunother. 58(1), 61-69 (2009). •• Data presented show a benefit for colon carcinoma patients when they are vaccinated with autologous tumor cells previously modified by infection with Newcastle disease virus.
101. Liang W, Wang H, Sun TM et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J. Gastroenterol. 9(3), 495-498 (2003). •• Shows an advantage to treated patients in terms of progression-free survival and overall survival. The protocol was different from the one described for autologous tumor vaccine-Newcastle disease virus since it consists of the separate application of autologous tumor and Newcastle disease virus.
102. Schirrmacher V, Fournier P. Newcastle disease virus: a promising vector for viral therapy of cancer. In: Viral Therapy of Cancer. Harrington KJ, Pandha HS, Vile RG (Eds). Wiley Publishers, NJ, USA (2008).
103. Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the DeCOG. Ann. Oncol. 17(4), 563-570 (2006).
104. Gao J, Chen M, Ren H. Clinical effects of dendritic cells pulsed with autologous hepatoma cell lysates on the postoperative recurrence and metastasis of hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 13(6), 432-435 (2005). •• Shows a survival benefit in terms of survival for cancer patients treated with dendritic cells and autologous tumor cell lysates.
105. Harzstark AL, Small EJ. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert Opin. Biol. Ther. 7(8), 1275-1280 (2007).
106. Harzstark AL, Small EJ. Sipuleucel-T for the treatment of prostate cancer. Drugs Today (Barc.) 44(4), 271-278 (2008).
107. Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18(23), 3894-3903 (2000).
108. Price N. Improved survival benefit of autologous dendritic cell-based vaccine for hormone refractory prostate cancer: a retrospective subset analysis of the d9901 trial. Clin. Prostate Cancer 2(4), 212 (2004). •• Shows improved overall survival but not progression-free survival of prostate cancer patients treated with autologous dendritic cells loaded with a fusion protein such as tumor-associated antigen.
109. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24(19), 3089-3094 (2006).
110. Schellhammer PF, Hershberg RM. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World J. Urol. 23(1), 47-49 (2005).
111. DeVita VT Jr. The Provenge decision. Nat. Clin. Pract. Oncol. 4(7), 381 (2007).
112. Moyad MA. What happened to the Provenge (Sipuleucel-T) vaccine for hormone refractory prostate cancer? Urol. Nurs. 27(3), 256-257 (2007).
113. Kalani AD, Jack A, Montenegro G, Degliuomini J, Wallack MK. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma. G. Ital. Dermatol. Venereol. 143(1), 59-70 (2008).
114. Hoos A, Parmiani G, Hege K et al. Cancer Vaccine Clinical Trial Working Group. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 30(1), 1-15 (2007).
115. Arlen PM, Gulley JL, Todd N et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J. Urol. 174(2), 539-546, (2005).
116. Lindsey KR, Gritz L, Sherry R et al. Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin Cancer Res. 12(8), 2526-2537 (2006)
117. National Cancer Institute www.cancer.gov/clinicaltrials
118. Discontinuation of Onercept in moderateto-severe psoriasis and Canvaxin in stage IV melanoma. Medical News Today, 9 April 2005 www.medicalnewstoday.com/ medicalnews.php?newsid=22446
119. CancerVax announces results of Phase III clinical trials of Canvaxin in patients with stage III and IV melanoma. Market Wire, 24 March 2006 www.marketwire.com/mw/release_html_b1?release_id=114480
120. Cellular, Tissue and Gene Therapies Avisory Committee Sipuleucel-T briefing document (BLA STN 125197/0). Seattle, WA: Dendreon Corporation; March 29, 2007 www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4291b1_01.pdf
121. Dendreon announced FDA advisory committee reviewed Provenge for hormone refractory prostate cancer. Dendreon Press Release date: 29 March 2007 www.dendreon.com